Large Long-Term Study Finds Modern Hormone Replacement Therapy Not Linked to Heart Disease Risk in Women 45-59

A study of over 52,000 women in Israel found that contemporary hormone replacement therapy did not increase the risk of heart attack, stroke, blood clots, or death among women ages 45 to 59, potentially easing long-standing safety concerns.

Chicago Metrowire Staff
••Healthcare
Large Long-Term Study Finds Modern Hormone Replacement Therapy Not Linked to Heart Disease Risk in Women 45-59

A large, long-term study of more than 52,000 women in Israel found that initiating contemporary hormone replacement therapy (HRT) was not associated with an increased risk of heart attack, stroke, blood clots or death among women ages 45 to 59. The preliminary findings, presented at the American Heart Association’s Scientific Sessions 2026, add to growing evidence that today’s HRT formulations may be safer for the heart than older versions that fueled decades of caution.

The study matters because fear of heart harm is a leading reason women decline hormone therapy for menopause symptoms, and why some clinicians hesitate to prescribe it. Lead researcher Ronen Arbel, Ph.D., of Clalit Health Services in Tel Aviv, said concerns about cardiovascular effects have long shaped treatment decisions. Previous randomized trials produced mixed results, but much of that evidence involved older, higher-dose formulations no longer commonly used and women who started HRT long after menopause. Current guidelines recommend starting HRT within 10 years of menopause onset and before age 60.

In the new study, researchers matched 52,330 women ages 45 to 59 with no history of heart disease, blood clots or cancer. Half had started HRT, primarily oral or transdermal (patch or gel), while the other half had not. After an average follow-up of 12 years, cardiovascular outcomes were similar. Heart attack, stroke or related heart disease occurred in 4.4% of the HRT group versus 4.6% of the no-HRT group. Death before age 80 occurred in 1.3% versus 1.2%, and blood clots occurred in 0.33% of both groups. Results were consistent across all HRT formulations and administration routes.

“Our results indicate that, for women in their mid-forties to late fifties with no history of heart disease or blood clots, the currently available hormone therapies prescribed to manage menopause symptoms do not appear to raise the risk of heart attack, stroke, clots or early death, even after long-term use,” Arbel said. Stacey E. Rosen, M.D., FAHA, past volunteer president of the American Heart Association, said the findings can help women and their healthcare teams have more informed conversations about benefits and risks.

The study assessed whether HRT was associated with atherosclerotic cardiovascular disease, venous thromboembolism or premature death. It is observational and cannot prove cause and effect, and researchers noted possible differences in lifestyle and symptom severity not captured in health records. The full abstract and the Online Program Planner are available, along with a Spanish news release. The findings are considered preliminary until published in a peer-reviewed journal.

The results align with other recent developments, including an American Heart Association news release noting that Perimenopause may offer a “window of opportunity” for heart disease prevention in women and a 2020 scientific statement on Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention. The study was presented at Scientific Sessions 2026, a premier global exchange of cardiovascular science.

Blockchain Registration

QR Code for Blockchain Registration